Upcoming Events

There are no upcoming events at this time.

ALTG 11/002 Temozolomide and PARPI as 2LC for SCLC

Phase I/II study of temozolomide and PARP (Poly ADP ribose polymerase) inhibitor as a second line chemotherapy for SCLC. This study concept is on hold and will be reviewed once the results of an ongoing Phase 1 study at UCLA exploring the combination are available.

Any further enquiries regarding this trial should be directed to the CTC Clinical Lead A/Prof Martin Stockler, atmartin.stockler@sydney.edu.au